Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy

Peptide receptor radionuclide therapy (PRRT) has been used for more than 20 y as a systemic treatment approach in inoperable or metastatic somatostatin receptor-positive tumors. The purpose of this study was to analyze the long-term outcome of PRRT with regard to the most commonly used radiopharmace...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Nuclear Medicine 2019-04, Vol.60 (4), p.524-529
Hauptverfasser:	Gabriel, Michael, Nilica, Bernhard, Kaiser, Bernhard, Virgolini, Irene J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anemia Disease control Female Follow-Up Studies Humans Kidney diseases Lutetium isotopes Male Medical prognosis Metastases Metastasis Middle Aged Neoplasms - diagnostic imaging Neoplasms - metabolism Neoplasms - radiotherapy Octreotide - adverse effects Octreotide - analogs & derivatives Octreotide - therapeutic use Patients Peptides Radiation therapy Radioisotopes Receptors, Peptide - metabolism Receptors, Somatostatin - metabolism Retrospective Studies Side effects Somatostatin Survival Analysis Treatment Outcome Tumors Yttrium isotopes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!